Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol
Status:
Completed
Trial end date:
1998-09-01
Target enrollment:
Participant gender:
Summary
The aim of the present study was to evaluate the ability of several doses of NOMAC in
combination with E2 to inhibit ovulation and to assess changes in the gonadotropin and
ovarian hormone profiles, in comparison to a control cycle in healthy-volunteer premenopausal
women.
The study was also designed to check whether the combined administration of E2 and NOMAC at
the dose of 2.5 mg daily induces any changes in the effects of the progestin compared to when
it is given alone.